Steven Harris, MD
Endocrinology, Diabetes & Metabolism · Greenbrae, CANPI 1104847532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $416,279 of the $564,457 with a category attached, or 73.7%. Amgen accounts for 66.0% of it on its own, with 5 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $846.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$373K
- Radius Health, Inc.$117K
- Ascendis Pharma Endocrinology Inc$72K
- Kyowa Kirin, Inc.$3K
- Lilly USA, LLC$21
- Romark Laboratories, LC$11
What the payments were for
- Consulting fees$38,3567%
- Speaking & faculty fees$416,27974%
- Travel & lodging$88,57316%
- Food & beverage$11,4692%
- Education$9,7792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 442 | $372,707 |
| Radius Health, Inc. | 138 | $117,308 |
| Ascendis Pharma Endocrinology Inc | 79 | $71,808 |
| Kyowa Kirin, Inc. | 6 | $2,601 |
| Lilly USA, LLC | 1 | $21 |
| Romark Laboratories, LC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$564,457 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 16 | $25,022 |
| Alendronate Sodium | 208 | $2,325 |
| Raloxifene Hcl | 40 | $1,867 |
| SynthroidLevothyroxine Sodium | 14 | $1,783 |
| Levothyroxine Sodium | 11 | $228 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Greenbrae
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.